167 related articles for article (PubMed ID: 23473309)
1. Strategies to reduce HERG K+ channel blockade. Exploring heteroaromaticity and rigidity in novel pyridine analogues of dofetilide.
Carvalho JF; Louvel J; Doornbos ML; Klaasse E; Yu Z; Brussee J; IJzerman AP
J Med Chem; 2013 Apr; 56(7):2828-40. PubMed ID: 23473309
[TBL] [Abstract][Full Text] [Related]
2. Exploring chemical substructures essential for HERG k(+) channel blockade by synthesis and biological evaluation of dofetilide analogues.
; Guo D; Klaasse E; de Vries H; Brussee J; Nalos L; Rook MB; Vos MA; van der Heyden MA; Ijzerman AP
ChemMedChem; 2009 Oct; 4(10):1722-32. PubMed ID: 19725081
[TBL] [Abstract][Full Text] [Related]
3. Allosteric modulators of the hERG K(+) channel: radioligand binding assays reveal allosteric characteristics of dofetilide analogs.
Yu Z; Klaasse E; Heitman LH; Ijzerman AP
Toxicol Appl Pharmacol; 2014 Jan; 274(1):78-86. PubMed ID: 24200993
[TBL] [Abstract][Full Text] [Related]
4. Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel.
Singleton DH; Boyd H; Steidl-Nichols JV; Deacon M; Groot MJ; Price D; Nettleton DO; Wallace NK; Troutman MD; Williams C; Boyd JG
J Med Chem; 2007 Jun; 50(13):2931-41. PubMed ID: 17536794
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships of pentamidine-affected ion channel trafficking and dofetilide mediated rescue.
Varkevisser R; Houtman MJ; Linder T; de Git KC; Beekman HD; Tidwell RR; Ijzerman AP; Stary-Weinzinger A; Vos MA; van der Heyden MA
Br J Pharmacol; 2013 Jul; 169(6):1322-34. PubMed ID: 23586323
[TBL] [Abstract][Full Text] [Related]
6. Acidification alters antiarrhythmic drug blockade of the ether-a-go-go-related Gene (HERG) Channels.
Dong DL; Li Z; Wang HZ; Du ZM; Song WH; Yang BF
Basic Clin Pharmacol Toxicol; 2004 May; 94(5):209-12. PubMed ID: 15125690
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological inhibition of the hERG potassium channel is modulated by extracellular but not intracellular acidosis.
DU CY; El Harchi A; Zhang YH; Orchard CH; Hancox JC
J Cardiovasc Electrophysiol; 2011 Oct; 22(10):1163-70. PubMed ID: 21489024
[TBL] [Abstract][Full Text] [Related]
8. Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.
Milnes JT; Witchel HJ; Leaney JL; Leishman DJ; Hancox JC
J Pharmacol Toxicol Methods; 2010; 61(2):178-91. PubMed ID: 20172036
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of hERG closure allow novel insights into hERG blocking by small molecules.
Schmidtke P; Ciantar M; Theret I; Ducrot P
J Chem Inf Model; 2014 Aug; 54(8):2320-33. PubMed ID: 25000969
[TBL] [Abstract][Full Text] [Related]
10. Removal of human ether-à-go-go related gene (hERG) K+ channel affinity through rigidity: a case of clofilium analogues.
Louvel J; Carvalho JF; Yu Z; Soethoudt M; Lenselink EB; Klaasse E; Brussee J; Ijzerman AP
J Med Chem; 2013 Dec; 56(23):9427-40. PubMed ID: 24224763
[TBL] [Abstract][Full Text] [Related]
11. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of negative allosteric modulators of the Kv11.1(hERG) channel.
Yu Z; van Veldhoven JP; 't Hart IM; Kopf AH; Heitman LH; IJzerman AP
Eur J Med Chem; 2015 Dec; 106():50-9. PubMed ID: 26519929
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias.
Potet F; Lorinc AN; Chaigne S; Hopkins CR; Venkataraman R; Stepanovic SZ; Lewis LM; Days E; Sidorov VY; Engers DW; Zou B; Afshartous D; George AL; Campbell CM; Balser JR; Li M; Baudenbacher FJ; Lindsley CW; Weaver CD; Kupershmidt S
J Biol Chem; 2012 Nov; 287(47):39613-25. PubMed ID: 23033485
[TBL] [Abstract][Full Text] [Related]
14. [3H]dofetilide binding in SHSY5Y and HEK293 cells expressing a HERG-like K+ channel?
Finlayson K; Pennington AJ; Kelly JS
Eur J Pharmacol; 2001 Feb; 412(3):203-12. PubMed ID: 11166283
[TBL] [Abstract][Full Text] [Related]
15. F463L increases the potential of dofetilide on human ether-a-go-go-related gene (hERG) channels.
Cheng G; Wu J; Han W; Sun C
Microsc Res Tech; 2018 Jun; 81(6):663-668. PubMed ID: 29573040
[TBL] [Abstract][Full Text] [Related]
16. Altering extracellular potassium concentration does not modulate drug block of human ether-a-go-go-related gene (hERG) channels.
Limberis JT; Su Z; Cox BF; Gintant GA; Martin RL
Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1059-65. PubMed ID: 17042915
[TBL] [Abstract][Full Text] [Related]
17. Role of the pH in state-dependent blockade of hERG currents.
Wang Y; Guo J; Perissinotti LL; Lees-Miller J; Teng G; Durdagi S; Duff HJ; Noskov SY
Sci Rep; 2016 Oct; 6():32536. PubMed ID: 27731415
[TBL] [Abstract][Full Text] [Related]
18. Inactivation gating determines drug potency: a common mechanism for drug blockade of HERG channels.
Yang BF; Xu DH; Xu CQ; Li Z; Du ZM; Wang HZ; Dong DL
Acta Pharmacol Sin; 2004 May; 25(5):554-60. PubMed ID: 15132818
[TBL] [Abstract][Full Text] [Related]
19. Understanding of molecular substructures that contribute to hERG K+ channel blockade: synthesis and biological evaluation of E-4031 analogues.
Vilums M; Overman J; Klaasse E; Scheel O; Brussee J; IJzerman AP
ChemMedChem; 2012 Jan; 7(1):107-13. PubMed ID: 21919210
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of DC031050, a class III antiarrhythmic agent, on hERG channel and three neuronal potassium channels.
Li P; Sun HF; Zhou PZ; Ma CY; Hu GY; Jiang HL; Li M; Liu H; Gao ZB
Acta Pharmacol Sin; 2012 Jun; 33(6):728-36. PubMed ID: 22609836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
